GNLX Insider Trading
Insider Ownership Percentage: 9.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,259,755.94
Genelux Share Price & Price History
Current Price: $2.46
Price Change: ▲ Price Increase of +0.12 (5.13%)
As of 04/11/2025 05:00 PM ET
Genelux Insider Trading History
Genelux Institutional Trading History
Data available starting January 2016
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Read More on Genelux
Volume
183,605 shs
Average Volume
211,079 shs
Market Capitalization
$85.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Genelux?
Genelux's top insider shareholders include:
- Aladar Szalay (Major Shareholder)
- John Thomas (Director)
- Yong Yu (VP)
- James L Tyree (Director)
- Sean Ryder (General Counsel)
- Caroline Jewett (Insider)
- Thomas Zindrick (CEO)
- John W Smither (Director)
- Joseph Cappello (VP)
- Doug Samuelson (CFO)
Learn More about top insider investors at Genelux.